Abstract
Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) is a severe mitochondrial disorder featuring multi-organ dysfunction. Mutations in either the ETFA, ETFB, and ETFDH genes can cause MADD but very little is known about disease specific mechanisms due to a paucity of animal models. We report a novel zebrafish mutant dark xavier (dxavu463) that has an inactivating mutation in the etfa gene. dxavu463 recapitulates numerous pathological and biochemical features seen in patients with MADD including brain, liver, and kidney disease. Similar to children with MADD, homozygote mutant dxavu463 zebrafish have a spectrum of phenotypes ranging from moderate to severe. Interestingly, excessive maternal feeding significantly exacerbated the phenotype. Homozygous mutant dxavu463 zebrafish have swollen and hyperplastic neural progenitor cells, hepatocytes and kidney tubule cells as well as elevations in triacylglycerol, cerebroside sulfate and cholesterol levels. Their mitochondria were also greatly enlarged, lacked normal cristae, and were dysfunctional. We also found increased signaling of the mechanistic target of rapamycin complex 1 (mTORC1) with enlarged cell size and proliferation. Treatment with rapamycin partially reversed these abnormalities. Our results indicate that etfa gene function is remarkably conserved in zebrafish as compared to humans with highly similar pathological, biochemical abnormalities to those reported in children with MADD. Altered mTORC1 signaling and maternal nutritional status may play critical roles in MADD disease progression and suggest novel treatment approaches that may ameliorate disease severity.
Highlights
Multiple acyl-CoA dehydrogenase deficiency (MADD), known as glutaric aciduria type II (GA-II, OMIM #231680), is a rare autosomal recessive inherited metabolic disorder first described in 1976 [1]
We report a novel zebrafish model of mitochondrial disease by inactivating the etfa gene
We report that etfa gene function is highly conserved in zebrafish as compared to humans
Summary
Multiple acyl-CoA dehydrogenase deficiency (MADD), known as glutaric aciduria type II (GA-II, OMIM #231680), is a rare autosomal recessive inherited metabolic disorder first described in 1976 [1]. The ETFA and ETFB gene products, ETFa and ETFb respectively, form an ETF heterodimer located in the mitochondria matrix [3]. This complex receives electrons from at least nine distinct dehydrogenases that are involved in fatty acid b-oxidation, amino acid and choline metabolism [4,5,6,7]. Type 3 patients have later onset and an overall milder course. They still have hypoglycemia, metabolic acidosis, cardiomyopathy, hepatomegaly, kidney defects and neurological manifestations such as encephalopathy and leukodystrophy [10,11]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.